Publications by authors named "Charles Molta"

Claim this Profile
F
Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.
Hong J Kan, Kirill Dyagilev, Peter Schulam, Suchi Saria, Hadi Kharrazi, Charles T Molta

Arthritis Res Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presentation of SLE in UK primary care using the Clinical Practice Research Datalink.
Alison L Nightingale, Julie E Davidson, Charles T Molta, Hong J Kan, Neil J McHugh

Lupus Sci Med· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.
Ronald F van Vollenhoven, Michelle Petri, Daniel J Wallace, David A Roth, Charles T Molta

Arthritis Rheumatol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
Hong Kan, Saurabh Nagar, Jeetvan Patel, Daniel J Wallace, Charles Molta

Clin Ther· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-marketing experiences with belimumab in the treatment of SLE patients.
Anca D Askanase, Jinoos Yazdany, Charles T Molta

Rheum Dis Clin North Am· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of systemic lupus erythematosus on employment and work productivity: data from a large cohort in the southeastern United States.
Cristina Drenkard, Gaobin Bao, Greg Dennis, Hong J Kan, Priti M Jhingran, Charles T Molta

Arthritis Care Res (Hoboken)· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.
Hong Kan, Annie Guerin, Michael S Kaminsky, Andrew P Yu, Eric Q Wu, Charles Molta

J Med Econ· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare utilization and costs of systemic lupus erythematosus in Medicaid.
Hong J Kan, Xue Song, Barbara H Johnson, Benno Bechtel, Donna O'Sullivan, Charles T Molta

Biomed Res Int· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).
Robert Strohal, Luis Puig, Edgardo Chouela, Tsen-Fang Tsai, Jeffrey Melin, Charles T Molta

J Dermatolog Treat· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study.
Enno Christophers, Siegfried Segaert, Gary Milligan, Charles T Molta, Robert Boggs

J Dermatolog Treat· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus.
Manan Shah, Sham Chaudhari, Trent P McLaughlin, Hong J Kan, Benno Bechtel, Charles T Molta

Clin Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set.
Oliver FitzGerald, Philip Helliwell, Philip Mease, Aizad Mumtaz, Laura Coates, Charles Molta

Ann Rheum Dis· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
Ian Landells, Amy S Paller, David Pariser, Gregory Kricorian, Joanne Foehl, Charles Molta

Eur J Dermatol· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Wolfram Sterry, Jean-Paul Ortonne, Bruce Kirkham, Olivier Brocq, Deborah Robertson, Charles T Molta

BMJ· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis